Institute of Clinical Research (India), ICRI, India's premiere institution in clinical research studies, in association with Department of Science & Technology, Government of India is holding a two-day international conference on Clinical Research & Development in India from April 14 - 15, 2007 at National Institute of Advance Studies, IISC Auditorium, Bangalore. Bangalore.

The conference will be preceded by a two-day training workshop on Pharmacovigilance organized by ICRI and World Health Organisation (WHO).

Bangalore will host experts from Indian and International regulatory, industry and academia such as Dr K K Tripathi, Advisor with the Department of Biotechnology, Government of India, Dr Sten Olsson and Dr Ronald Meyboom from WHO, Dr N K Ganguly, Director General, Indian Council of Medical Research (ICMR), Government of India, Dr Laxman Prasad, Advisor, Department of Science and Technology, Government of India, Dr Nermeen Varawalla, Vice President, PRA, USA, and all leading pharmaceutical companies like Ranbaxy, Quintiles, Dr Reddy's, Panacea Biotec, Fortis, Merck, Novo Nordisk, Unichem, etc during the two-day conference.

Keynote lectures, workshops, and parallel discussion and Q&A sessions will be highlight of the conference.

Dr S K Gupta, Dean, ICRI, said, "Bangalore is fast emerging as the hub of clinical research and hence we decided to host this international conference in this beautiful city. Besides discussing the regulatory principles and procedures in clinical research, this conference aims at providing a platform for an interaction amongst the stakeholders from the field of Clinical Research across the world, review and evaluation of clinical research environment in India. It is extremely important to address all India-specific issues that are considered barriers to global clinical development and which have discouraged most companies from exploring India for implementing their global development plan."

This conference will provide a platform at an international level to address issues related to conduct of Clinical Trials protecting the subject rights and well being. It will also give an opportunity to discuss the changing regulatory requirements for participating in global clinical trials. The meeting will be attended by senior executives, managers and investigators from industry and academia projecting problems associated with compliance to ICH guide lines and national regulatory bodies of India and other countries. Development and implementations of safety guidelines for bio product research and their Therapeutic Evaluation will also be discussed in the meeting. Eminent speakers will also focus on risk management strategies at all stages of new drug development and Clinical Research.

ICRI is India's first and only Clinical Research Institute. ICRI has been conceived with the objective of meeting the growing demand of skilled Clinical Research professionals in the future. The choice of courses offered by the Institution is specially made to suit the requirements of a large number of people with varied experiences. ICRI currently operates from three campuses in Mumbai, Delhi and Bangalore, and is supported by excellent faculty drawn from the best in the industry and visiting faculty from Cranfield University UK.